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Introduction
Colorectal cancer is the fourth commonest worldwide
form of cancer with more than 700.000 individuals each
year (1), representing an incidence of 40 per
100.000 patients in Belgium. Regional recurrence of
colorectal cancer in the peritoneal cavity carries a very
poor prognosis (2) with a mean and median overall sur-
vival times of 6.9 and 5.2 months (3).
The predominant patterns of  peritoneal spread, con-
cerning 20 to 50% of colorectal cancer recurrences, has
provided the impetus for a locoregional approach em-
ploying intraperitoneal perfusion of cytotoxic agents (4).
Hyperthermic intraperitoneal chemotherapy (HIPEC)
has the advantages of bathing the entire cavity and per-
mitting very high local drug concentration to be
reached (5). However, it is ineffective when used without
maximal cytoreduction because cytotoxic agents only
penetrate tumour nodule superficially to a depth of less
than 2 mm (6). Theoretically, HIPEC can increase local
drug exposure with less systemic toxicity when com-
pared with conventional chemotherapy. Hyperthermia
has a direct cytotoxic effect and enhances the activity and
the penetration depth of many cytotoxic drugs.
Although MMC is still considered as the gold
standard in HIPEC since this is the only regimen that has
proven its efficacy in a phase III trial, oxaliplatin is
considered as an alternative of choice in HIPEC for its
significant activity in advanced colorectal cancer,
despite a grade 3-4 haematological toxicity rate of
58% (7).
We report a retrospective study on 21 consecutive
patients treated by complete cytoreduction and HIPEC
for colorectal peritoneal carcinomatosis (PC). We first
used MMC scheme, then we switched for oxaliplatin
HIPEC. We propose to compare complications rate of
these two groups.
Material and methods
From February 1998 to February 2004, 21 patients with
colorectal PC were treated curatively in our centre.
There were 11 males and 10 females, with a mean age of
56.5 years (range 33-79 years). The PC arose from ade-
nocarcinoma of colon in 17 patients and from rectum in
4 patients. PC was diagnosed as recurrence in
14 patients (66%) while in 7 cases (33%) it was found
during treatment of the primary tumour.
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Abstract. Background : Peritoneal carcinomatosis (PC) from colo-rectal cancer carries a very poor prognosis with a
mean and median overall survival times of 6.9 and 5.2 months. It has been proved that a locoregional therapeutic
approach of this disease with cytoreduction followed by hyperthermic intraperitoneal chemotherapy (HIPEC) improved
survival of these patients. However, this combined treatment presents a high complication rate.
Methods : 21 patients with PC of colorectal origin underwent complete cytoreduction followed by HIPEC using
Mitomycin-C (13 patients) or oxaliplatin (8 patients) and the open coliseum technique. For each case the medical datas
were retrospectively analysed to determine feasibility, morbidity, mortality, survival time and prognostic factors.
Results : All patients presented a Sugarbaker’s Peritoneal Cancer index inferior to 15. The mean operating time was
453 minutes. After a median follow-up of 24.9 months, actuarial disease-free survival was 36.6% at 5 years. The medi-
an survival time was 34 months. The morbidity rate was 33.3% with a significant higher complication rate in the oxali-
platin group (5/8) than in the Mytomycin-C (MMC) group (2/13). One patient (4.7%) died two months after treatment
with MMC (endocarditis).
Conclusions : This series confirm positive impact of cytoreduction and HIPEC on PC. We obtained a moderated
complications rate thanks to a high degree of selection of the patient. Oxaliplatin scheme is responsible of a higher
morbidity than in MMC group. Phase III trial comparing these two drugs is needed.
The abdomen was approached trough a xyphopubic
incision. The extent of the PC was scored using
peritoneal index described by SUGARBAKER (8).
Complete resection (or electrocauterisation) of all
macroscopically visible lesions of PC was required
before HIPEC. If complete resection (residual tumour
< 1 mm in diameter) was not possible, the procedure was
contraindicated and the laparotomy was closed.
In 5 patients (23%), we performed resection of syn-
chronous liver metastases with one right hepatectomy,
one segmentectomy III and three localised tumorec-
tomies. No patients presented indications of radio-
frequence resection.
HIPEC was performed intra operatively. A continu-
ous closed circuit was used with three thermal probes
placed inside the peritoneal cavity. The skin surrounded
the laparotomy was sutured to a retractor placed above
the anterior surface of the abdomen, causing an elevated
“coliseum” rim around.
The first 13 patients were treated with MMC alone
(10 mg/m2) and other 8 received 460 mg/m2 of oxali-
platin in 2 l/m2 of dextrose at 5% for the HIPEC associ-
ated to a systemic chemotherapy of 5-FU (400 mg/m2)
and folic acid (20 mg/m2) given one hour prior the
HIPEC infusion. HIPEC lasted 90 minutes in the first
group and 30 minutes in the second group, at a peri-
toneal temperature of between 41 and 42.5°C.
Radiotherapy was proposed before intervention in 2
of 4 cases of rectal adenocarcinoma and 16 patients of
the entire population received chemotherapy after
HIPEC.
We used a Kaplan-Meier method for the establish-
ment of overall and disease free survival of all patients.
However, the comparison of complications due to MMC
or Oxaliplatin HIPEC was feasible and powered by a
Chi-square test.
Results
All patients presented a PC index < 15 and the mean
peritoneal index was 8.28 (range 3-15). HIPEC with
MMC or Oxaliplatin were realised only if the cyto-
reduction was complete. No patient presented ascitis or
bowel obstruction. The MMC group and the Oxaliplatin
group were comparable in term of metastases,
Karnofsky performance status and peritoneal cancer
index (Table I).
Pathological examination of the resected tumours
revealed a UICC staging of II in 4 patients, III in
7 patients and IV in 10. The mean number of resected
organs was 2. The treatment of primary tumour needed
one total colectomy, two ileo-caecal resections, two
anterior rectal resections and two left hemi-colectomies.
For the cytoreduction of PC and recurrences, we per-
formed one ileo-caecal resection, one anterior rectal
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resection, two left hemi-colectomies, nine small bowel
resection, five total hysterectomies, one bladder resec-
tion, four omentectomies, two caudal pancreatectomies
and two splenectomies.
The mean operating time was 453 minutes (range 315
to 750 min).
Overall and disease free survival rates among the
entire population were respectively 88.7% and 72.6% at
1 year, 72.9% and 37.1% at 2 years, 45.5% and 36.6% at
3 years, 36.6% both at 4 and 5 years. The median sur-
vival time was 34 months (Fig. 1 and 2). After a median
follow-up of 24.9 months (range 2 to 80 months), cancer
recurrence was detected in 8 patients (38.0%). MMC
and oxaliplatin groups were not comparable in term of
survival because of the low follow-up of the oxaliplatin
group (Fig. 3).
One patient died during post operative period,
2 months after HIPEC. Minor and major complications
occurred in 7 (33.3%) patients with reoperation in 5.
Anastomotic leakage represented the most current com-
plications in the post operative period, without significa-
tive difference between MMC and Oxaliplatin groups.
However, we noticed a significative difference of total
morbidity in term of number of complicated patients
(p < 0.05) with 5 patients attached to the oxaliplatin
group (5/8) and 2 to the MMC group (2/13). Number of
complications were also different (p < 0.001) with a
higher morbidity of the oxaliplatin group (Table II).
Even though the smal number of patients included in
our study doesn’t permit to obtain significative results,
we noticed several factors influencing survival (9).
Table I
Comparison of both groups
MMC Oxaliplatin
Number of patients 13 8 p
Karnofsky performance
status
100% 1/13 2/8 NS
90% 7/13 5/8 NS
80% 2/13 0/8 NS
70% 2/13 1/8 NS
Ascitis 0/13 0/8 NS
Obstruction 0/13 0/8 NS
Cytoreduction
RO 13/13 8/8 NS
R1 0/13 0/8 NS
R2 0/13 0/8 NS
Metastases 7/13 3/8 NS
Peritoneal cancer index
< 10 10/13 4/8 NS
> 10 3/13 4/8 NS
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The presence of associated metastases seems to have
a negative impact with 4-year overall survival rates of
17.5% and 58% without metastases (p < 0.28) (Fig. 4).
Our study doesn’t confirm the negative impact on sur-
vival of the peritoneal cancer index (p < 0.34).
Discussion
Complete treatment of PC by cytoreduction and HIPEC
has positive impact on survival (10). Several other trials
of HIPEC without preliminary maximal cytoreduction
surgery described a 5-year survival rate of 0 % (11).
However, a complete stripping of all the peritoneum
including normal tissue is unnecessary and can result in
a high incidence of post operative complications (10).
Fig. 1







Number of interventions 13 8 p
Complicated patients 2/13 5/8 p < 0,05
Complications (22)
Grade II (pharmacological treatment)
Ascitis infection 1 NS
Grade IIIa (radiological intervention under local anesthesia)
Sub-liver abcess 1 NS
Anastomotic leakage 1 NS
Grade IIIb (surgical reintervention under general anesthesia)
Anastomotic leakage 2 2 NS
Bowel leakage 1 NS
Ureteral injury 1 NS
Hemothorax 1 NS
Grade V
Post operative death 1 NS
Total complications 3 8 p < 0,001
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We applied this consideration and we could obtain a
moderated morbidity and mortality rates (Table III).
The peritoneal carcinomatosis index (PCI), based on
a cut off of 16 for ELIAS et al (5) or 10 and 20 for
SUGARBAKER et al (10), has shown a major impact on sur-
vival. The encouraging results of our serie could also be
attributed to patients who presented a peritoneal carci-
nomatosis index (PCI) lower than 15, allowing a moder-
ated cytoreduction surgery.
Many authors have proved that non peritoneal metas-
tases have a negative impact on survival after HIPEC (5,
10). In our serie, patients with liver metastases seem to
have a worth overall and disease free survival. In fact,
we do not recommand synchronous resection of liver
metastases. This technic must be reserved for exception-
nal case of alone and unifocal  tumor. HIPEC procedure
must be valided before to be associated with liver resec-
tion.
The study by EILBER et al. showed that post operative
adhesions prevented complete bathing of the peritoneal
cavity and that recurrent peritoneal disease was located
in drug “no go” areas (12). It’s the reason why we chose
HIPEC over early postoperative intraperitoneal
chemotherapy (EPIC). The coliseum technique permits
a high control of full peritoneal bathing and the surgeon,
with the thermal probes monitoring, regularise with pre-
cision the 41 to 42.5°C temperature of drug solution.
In HIPEC procedures, a direct activing cell cycle
independent cytotoxic agent is needed. We preferred
HIPEC over EPIC to avoid the “no go areas” where
drugs can not act because of post-operative adher-
ences (5) and because of the potentialisation of the cyto-
toxic action. 
We first chose MMC as chemotherapic agent because
of its known activity in colorectal cancer (13), its direct
cytotoxic effect, the thermal enhancement of its
activity (14), and penetration depth. However, clinical
trials and phase III MOSAIC study (15) have proved the
high Oxaliplatin efficacity on overall and disease free
survival in colorectal cancer. Preclinical study demon-
strated that the exposure of peritoneal surfaces to oxali-
platin was significantly increased by intraperitoneal
administration than with systemic treatment and hyper-
thermia showed a trend toward the enhancement of tis-
sue absorption of oxaliplatin (16). In phase I clinical
trial (17), oxaliplatin HIPEC showed a high tumour pen-
etration and a limited systemic absorption with a peri-
toneal absorption 25-fold than in plasma and no haema-
tological, renal nor hepatic toxicity. Ended, given the
potentiating effect of 5-FU on oxaliplatin (17) and the
impossibility of intraperitoneal administration, a perfu-
sion of 5-FU and folic acid has been proposed before
HIPEC. For these reasons, we have changed our MMC
protocol since 2001 for oxaliplatin HIPEC associated
with systemic 5-FU chemotherapy. 
The follow-up of the oxaliplatin group is still too
short to estimate differences on survival impact with
HIPEC with MMC. However, we noticed a morbidity
rate higher in the oxaliplatin group whereas the bathing
time is shorter (30’) than in MMC HIPEC (90’) and the
bathing temperature is the same in both group. Only one
phase II study of oxaliplatin HIPEC has been reported in
literature and no increased morbidity has been
described (18). These data must be confirmed with ran-
domised study. 
Fig. 4
Survival by metastase staging
Table III
Review of HIPEC series
MMC Oxaliplatin
Patients Nb Morbidity Mortality Patients Nb Morbidity Mortality
ROUERS A. et al. 13 23% 7,60% 8 62,50% 0%
(19) 102 65% 7,80%
(23) 506 22,40% 4%
(5) 64 66% 9,30%
(18) 24 41,60% 8%
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As many series (19), important part of our morbidity
is represented by leakages. It has been proved that the
use of heated chemotherapy has a detrimental effect on
the strength of colonic anastomosis, especially during
the early postoperative period (until day 10) (20, 21).
This may cause anastomotic failure and postoperative
morbidity. Therefore, careful selection and avoidance of
unnecessary anastomoses are mandatory.
Conclusion
As described in literature, we confirm the high morbidi-
ty in patients treated by HIPEC. However, median sur-
vival of our serie is very encouraging. Complication rate
with MMC, wich is considered as the gold standard in
HIPEC since this is the only regimen that has proven its
efficacy in a Phase III trial, seems to be lower than with
Oxaliplatin. Till  a comparative study is realised, we
recommand to be cautious with the use of Oxaliplatin in
HIPEC.
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